Neuro Care

Atomoxetine for ADHD, Product Strengths and Monitoring

A guide to the exact atomoxetine formulation and the follow-up needed during ADHD treatment.

By Global Medicines ExportPublished: Updated: Educational article

Reference table

Atomoxetine reference table

The catalogue contains several tablet and capsule presentations. The US STRATTERA reference cited here is for capsules. A different dosage form must be checked against its own product information.

Capsules, tablets and strength matching

Product detailWhy it mattersWhat to record
Strength per unitIdentifies the prescribed presentationExact milligrams
Tablet or capsuleFormulation instructions can differFull dosage form
Brand and manufacturerIdentifies the controlling leafletExact pack information
Units per packDefines the requested supply quantityPack count and packs ordered

The source product and country are identified in the article. Confirm personal treatment instructions with the prescribing clinician.

What atomoxetine is used for

Atomoxetine affects norepinephrine signalling and is used in ADHD care. Lilly's current US STRATTERA label includes adults and paediatric patients aged 6 years or over. Assessment should confirm the diagnosis and consider the person's broader mental and physical health.

Follow-up examines functioning and adverse effects as well as symptom ratings. Different people may respond at different speeds, so a clinician sets the review interval. New or worsening mood symptoms need attention while treatment is assessed rather than being assumed to reflect the original condition.

Capsules, tablets and strength matching

The catalogue contains several tablet and capsule presentations. The US STRATTERA reference cited here is for capsules. A different dosage form must be checked against its own product information.

The number of milligrams describes one unit. Dose planning can depend on body weight, liver function, medicines affecting metabolism and treatment response.

Monitoring mood, growth and treatment response

The US label has a boxed warning about increased suicidal ideation in short-term studies in children and adolescents with ADHD. Families and clinicians should watch for suicidal thoughts, clinical worsening or unusual behavioural changes, especially early in treatment and after dose changes.

Seek urgent help for immediate safety concerns. Report new manic or psychotic symptoms, marked aggression or major mood changes to the treating team. Children may need height and weight monitoring. Record useful observations about sleep, appetite and functioning for the scheduled review.

Heart, liver and interaction precautions

Before treatment, the clinician assesses cardiovascular history and relevant family history. Blood pressure and pulse require monitoring. Chest pain, fainting or other symptoms suggesting a cardiac problem need prompt assessment.

Report jaundice, dark urine or symptoms suggesting liver injury. Discuss MAO inhibitors and medicines that affect CYP2D6 metabolism with the prescriber. The product label also addresses glaucoma, pheochromocytoma and other contraindications. A pharmacist should check the complete medicine list before an additional treatment is started.

Administration and product enquiries

Follow the exact prescribed schedule and product leaflet. Ask a pharmacist about swallowing difficulties rather than opening or crushing a preparation without checking. The reference capsule information contains specific handling advice, including avoiding exposure to capsule contents.

A professional enquiry should state ingredient, strength, tablet or capsule form, exact brand if required, pack size, quantity and destination. Request manufacturer and leaflet information for the actual presentation. A catalogue listing does not complete an ADHD assessment or establish the product's eligibility in the receiving country. Keep personal psychiatric histories within secure clinical care.

Export product support

Need product, pack, and documentation details?

Global Medicines Export can support international B2B enquiries for product availability, strengths, pack information, quotation coordination, and shipment documentation review.

Common questions

Can every atomoxetine strength use one dosing chart?

The regimen depends on the person's assessment, body weight where relevant, liver function, interacting medicines and exact product label.

Why are mood changes monitored?

The reference label describes suicidal-ideation and behavioural risks that require close observation in younger patients and prompt clinical review when concerns arise.

Does the US capsule label cover a tablet brand?

That reference concerns STRATTERA capsules. A tablet preparation needs its own manufacturer and local product information.

Which measurements may be checked during follow-up?

The clinician may monitor blood pressure, pulse, treatment response, appetite and, in children, growth, alongside mental-health symptoms.

Important medical note

This article is for general educational information only. It is not medical advice, diagnosis, or a treatment plan. Medicines should be used only under the guidance of a qualified healthcare professional. Product availability, export documentation, and quotation support do not imply that a medicine is appropriate for any individual patient.

References